[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1983

Continued Propranolol Administration Following Coronary Bypass Surgery: Antiarrhythmic Effects

Author Affiliations

From the Division of Thoracic and Cardiovascular Surgery, Department of Surgery (Drs Abel, Gielchinsky, and Parsonnet), and the Division of Cardiology, Department of Medicine (Drs Pores and Ligouri), Newark (NJ) Beth Israel Medical Center (Mr van Gelder); and the Department of Surgery, New Jersey Medical School, College of Medicine and Dentistry of New Jersey (Drs Abel, Pores, Gielchinsky, and Parsonnet).

Arch Surg. 1983;118(6):727-731. doi:10.1001/archsurg.1983.01390060045010

• One hundred consecutive patients requiring propranolol hydrochloride before undergoing isolated aortocoronary bypass procedures were examined. In half the patients, propranolol therapy was discontinued, whereas the other half continued to receive intraoperative and postoperative propranolol regardless of clinical events. Although there were no preoperative differences in the apparent degree of coronary arterial disease or left ventricular function in the two groups, postoperative supraventricular arrhythmias were less frequent in the propranolol-treated group, most noticeably in those receiving < 320 mg preoperatively. In patients who had received large preoperative doses (≥320 mg/day), there were no significant differences in postoperative supraventricular tachycardias. Continued propranolol therapy following isolated coronary bypass surgery appears to be a safe and efficacious method of decreasing the incidence of postoperative supraventricular tachycardias.

(Arch Surg 1983;118:727-731)